Arcturus Therapeutics Holdings Inc. (ARCT)
| Market Cap | 233.89M +13.2% |
| Revenue (ttm) | 30.51M -68.7% |
| Net Income | -87.24M |
| EPS | -3.08 |
| Shares Out | 28.82M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 141,645 |
| Open | 8.00 |
| Previous Close | 7.97 |
| Day's Range | 7.95 - 8.59 |
| 52-Week Range | 5.50 - 17.96 |
| Beta | 2.61 |
| Analysts | Strong Buy |
| Price Target | 23.70 (+192.05%) |
| Earnings Date | Nov 5, 2026 |
About ARCT
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In additi... [Read more]
Financial Performance
In 2025, ARCT's revenue was $82.03 million, a decrease of -46.14% compared to the previous year's $152.31 million. Losses were -$65.78 million, -18.73% less than in 2024.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for ARCT stock is "Strong Buy." The 12-month stock price target is $23.7, which is an increase of 192.05% from the latest price.
News
Arcturus Therapeutics price target lowered to $40 from $41 at Roth Capital
Roth Capital lowered the firm’s price target on Arcturus Therapeutics (ARCT) to $40 from $41 and keeps a Buy rating on the shares. The firm notes Meiji Seika Pharma invested…
Arcturus Therapeutics announces $50M investment by Meiji Seika
Arcturus Therapeutics (ARCT) announced an expanded collaboration with Meiji Seika Pharma (MEJHY), including a $50M equity investment at an 80% premium. The expanded partnership includes a memorandum o...
Arcturus Therapeutics Announces $50 Million Investment by Meiji Seika Pharma as Part of Expanded Collaboration
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and ...
Arcturus Therapeutics Holdings Transcript: Guggenheim 3rd Annual Healthcare Innovation Conference
Two 2027 data catalysts are planned: CF phase II cohort 4 full data in Q2 and ARCT-2601 OTC deficiency top-line data in H2. LUNAR 2.0 showed 38-fold better performance in primates and is intended to support more convenient dosing and liver-disease programs.
Arcturus Therapeutics Holdings Earnings Call Transcript: Q3 2026
Clinical programs and LUNAR 2.0 advanced, with key ARCT-032 and ARCT-2601 milestones expected in 2027. Q3 revenue rose on a one-time CSL Seqirus termination payment, while cash runway extends through 2028.
Arcturus Therapeutics Holdings Earnings release: Q3 2026
Arcturus Therapeutics Holdings released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Arcturus Therapeutics Holdings Quarterly report: Q3 2026
Arcturus Therapeutics Holdings has published its Q3 2026 quarterly earnings report on November 5, 2026.
Arcturus Therapeutics Announces Third Quarter 2026 Financial Results and Pipeline Progress
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and ...
Arcturus Therapeutics Holdings Slides: Corporate presentation
Arcturus Therapeutics Holdings has posted slides in relation to its latest quarterly earnings report, which was published on November 3, 2026.
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 5, 2026
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and ...
Arcturus Therapeutics price target lowered to $20 from $23 at BTIG
BTIG lowered the firm’s price target on Arcturus Therapeutics (ARCT) to $20 from $23 and keeps a Buy rating on the shares after the company announced interim OTC deficiency Phase…
Arcturus Therapeutics upgraded to Buy from Neutral at Citi
Citi upgraded Arcturus Therapeutics (ARCT) to Buy from Neutral with a price target of $20, up from $8. The firm says ARCT-810’s clinical activity and ARCT-2601’s “bridge” improve the company’s…
Arcturus Therapeutics upgraded to Buy from Neutral at Citi
Citi upgraded Arcturus Therapeutics (ARCT) to Buy from Neutral with a $20 price target
Arcturus Therapeutics Holdings Transcript: Status update
Phase II data show ARCT-810 is safe, well-tolerated, and effective in normalizing ammonia and reducing glutamine in OTC deficiency, even with increased protein intake. LUNAR 2.0 enables higher protein expression, supporting lower, less frequent dosing. FDA supports integrating ARCT-2601 into the study, with pivotal pediatric trials and pipeline expansion planned.
Arcturus Therapeutics Holdings Press release: Status update
Arcturus Therapeutics Holdings issued a press release on September 23, 2026, disclosing material business information to investors.
Arcturus Therapeutics Holdings Slides: Status update
Arcturus Therapeutics Holdings has posted slides in relation to its latest quarterly earnings report, which was published on September 23, 2026.
Arcturus Therapeutics announces interim OTC deficiency Phase 2 results
The company states: “Arcturus Therapeutics (ARCT) announced encouraging interim Phase 2 results from ARCT-810 in ornithine transcarbamylase deficiency and introduced LUNAR 2.0, the Company’s next-gene...
Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company,” “Arcturus,” Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and ...
Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and ...
Arcturus Therapeutics Holdings Transcript: H.C. Wainwright 28th Annual Global Investment Conference
The session highlighted differentiated mRNA technologies, a robust rare disease pipeline, and regained global control of a leading COVID vaccine. Key near-term milestones include a phase II data readout for OTC deficiency and a pivotal phase III decision for the CF program, both with significant commercial and regulatory implications.
Arcturus Therapeutics Holdings Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Upcoming data readouts for liver (OTC deficiency) and lung (cystic fibrosis) mRNA programs are expected to shape the next year, with regulatory clarity and potential phase III advancement. The self-amplifying mRNA platform continues to generate revenue and attract interest for broader applications.
Arcturus Therapeutics Holdings Transcript: Citigroup’s Biopharma Back to School Summit 2026
Upcoming milestones include a phase II data and regulatory update for the OTC deficiency program and a Q4 go/no-go decision for the CF inhaled mRNA therapy, which could unlock $40M in funding. Both programs leverage advanced mRNA technologies and are supported by positive regulatory feedback and innovative partnerships.
Arcturus Therapeutics price target raised to $41 from $20 at Roth Capital
Roth Capital raised the firm’s price target on Arcturus Therapeutic (ARCT) s to $41 from $20 and keeps a Buy rating on the shares. Six months into the 12-week Cohort…
Arcturus Therapeutics to Participate in Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and ...
Arcturus Therapeutics Holdings Transcript: Canaccord Genuity's 46th Annual Growth Conference
The company is advancing two flagship mRNA programs for cystic fibrosis and OTC deficiency, both nearing phase III with significant unmet needs and commercial potential. A unique Thermo Fisher partnership supports CF development, while strong cash reserves and regained vaccine rights provide strategic flexibility.